0000008063-25-000059
SEC filingNet income swung to $10.8M on Aerospace strength and lower interest costs, offset by patent dispute charges.
For the six months ended June 28, 2025, Astronics reported consolidated sales of $410.6 million, up 7.2% from $383.2 million a year ago. Gross profit increased to $113.7 million (27.7% margin) from $103.1 million (26.9% margin), aided by higher Aerospace volume and improved mix. Net income reached $10.8 million ($0.30 per diluted share), compared with a net loss of $1.6 million ($0.05 per share) in the prior-year period. The improvement was driven by Aerospace sales growth, lower interest expense ($6.2M vs $11.6M) due to refinancing, and a $1.1M discrete tax benefit. However, SG&A rose $6.8M to $73.1M, largely due to a $9.7M reserve adjustment for the UK patent dispute, partially offset by lower litigation costs. In Q2 alone, sales grew 3.3% to $204.7M, but gross margin contracted to 25.8% from 28.0% due to $5.8M in Aerospace simplification charges and $6.4M in Test Systems cost revisions. Net income of $1.3M was essentially flat versus $1.5M in Q2 2024.
Aerospace: H1 sales rose 13.0% to $385.0M, driven by a 13.3% increase in Commercial Transport ($283.1M) and a 45.0% jump in Military Aircraft ($60.7M) from the FLRAA program. General Aviation declined 12.8%. Operating profit grew to $40.3M (10.5% margin) from $31.4M (9.2%), benefiting from volume leverage and $2.8M lower litigation costs, but offset by $6.5M in simplification initiatives and the $9.7M UK patent reserve. Bookings of $418.4M yielded a 1.09x book-to-bill.
Test Systems: Sales plunged 39.9% to $25.6M, with an operating loss of $8.9M (worse than $8.4M). The primary driver was $8.3M in revenue de-recognition from cost revisions on long-term mass transit contracts. Excluding those revisions, underlying performance was impacted by low volume and unfavorable mix. Restructuring savings were inadequate to offset the charges. Backlog rose to $74.5M, supported by $38.4M in H1 bookings (1.50x book-to-bill).
Management did not provide explicit quantitative guidance but highlighted ongoing challenges: supply chain pressures, tariff impacts (deemed not significant in Q2), and the UK patent dispute (paid $21.6M in Q2). Key priorities include executing on Aerospace growth (especially Boeing ramp-up), improving Test Systems profitability through cost actions and new business wins, and maintaining compliance with ABL covenants (minimum fixed charge coverage 1.10x, excess availability of 10% of borrowing base or $15M). The Convertible Notes are convertible due to stock price trigger, but no near-term liquidity concerns are flagged. The OBBBA tax law passed July 2025 is being evaluated for deferred tax impacts.
As of June 28, 2025, Astronics had $13.5M cash and cash equivalents, down from $18.4M at year-end 2024 (including restricted cash). Total debt stood at $159.3M, primarily consisting of $165M 5.500% Convertible Senior Notes due 2030 (net of unamortized debt issuance costs) and no outstanding balance on the $220M ABL revolver, leaving $197.8M available (net of $2.3M letters of credit). The ABL facility has a minimum fixed charge coverage ratio of 1.10x and a minimum excess availability of the greater of 10% of the borrowing base or $15M; the company was in compliance. Restricted cash was zero at June 28, 2025, compared to $9.1M at December 31, 2024, due to a cash dominion arrangement.
Total backlog (remaining performance obligations) was $645.4M, with $481.3M expected to be recognized over the next twelve months. Contract liabilities (customer advances and deferred revenue) were $27.8M, essentially flat from $28.2M at year-end. The company has a factoring agreement with Citibank for up to $45M per year, but it was not utilized. Product warranty accrual stood at $19.0M, up from $18.1M at the start of the year. A German patent litigation reserve of $17.3M is classified as non-current.
Share buyback program: $41.5M remaining authorization; no repurchases in the six months. No dividends. Debt change: net reduction of $9.4M (repayments of $11.1M vs proceeds of $1.1M). Capital expenditures were $6.7M (1.6% of sales), with $6.5M in Aerospace and $0.2M in Test Systems. The company also completed a $165M Convertible Notes offering in December 2024, which was not drawn further. Subsequent to quarter end, on June 30, 2025, the company acquired Envoy Aerospace for $8.3M (net of cash), with $4.5M paid at closing.
Aerospace segment (six months): sales $385.0M (+13.0% YoY), operating profit $40.3M (10.5% margin). Revenue by market: Commercial Transport $283.1M, Military Aircraft $60.7M, General Aviation $33.6M, Other $7.6M. By product line: Electrical Power & Motion $195.2M, Lighting & Safety $102.7M, Avionics $65.3M, Systems Certification $7.9M, Structures $6.3M. Test Systems segment: sales $25.6M (-39.9% YoY), operating loss $8.9M (-34.9% margin). All Test Systems revenue is Government & Defense. Geographic mix not disclosed in notes.